扬农化工（600486）：销量提升带动营收及利润同比增长

Investment Rating - The report maintains a "Buy" investment rating for the company [7][24]. Core Views - The company achieved a revenue of 6.234 billion yuan in the first half of 2025, representing a year-on-year growth of 9.38%, with a net profit of 806 million yuan, up 5.60% year-on-year [12][24]. - The increase in sales volume has driven revenue and profit growth, with the second quarter showing a revenue of 2.993 billion yuan, a year-on-year increase of 18.63% [12][24]. - The original drug business has seen significant growth, with revenue from original drugs, formulations, and trade reaching 3.655 billion, 1.171 billion, and 1.287 billion yuan respectively [2][13]. Revenue and Profit Analysis - The company reported a gross profit of 1.473 billion yuan in the first half of 2025, an increase of approximately 93 million yuan year-on-year, with a gross margin of 23.6%, down 0.6 percentage points [2][13]. - Domestic sales increased by 799.5 million yuan to 3.579 billion yuan, while overseas sales decreased by 260 million yuan to 2.655 billion yuan [2][13]. - The gross profit from original drugs, formulations, and trade was 1.031 billion, 312 million, and 105 million yuan respectively, with corresponding gross margins of 28.2%, 26.7%, and 8.2% [2][13]. Production and Sales Volume - The production volume for original drugs and formulations in the first half of 2025 was 57,800 and 25,500 tons, respectively, with sales volumes of 56,700 and 28,100 tons [3][15]. - The average selling price for original drugs was 64,500 yuan per ton, down 3.0% year-on-year, while the average selling price for formulations was 46,000 yuan per ton, down approximately 8.3% [3][15]. Future Growth Potential - The company is advancing the Liaoning Youchuang project, which is expected to provide new growth in the next 2-3 years, with a total investment budget of 3.48 billion yuan and a cumulative investment progress of 84.41% [4][23]. - Profit forecasts for the company indicate net profits of 1.47 billion, 1.78 billion, and 2.04 billion yuan for 2025 to 2027 [24].